
ImmunityBio (NASDAQ:IBRX) expects a recent expansion of its ANKTIVA bladder cancer label to contribute more substantially to sales in 2027, while the company prepares to seek another approval before the end of 2026, CEO Rich Adcock said at the Jefferies Global Healthcare Conference in London.
Adcock said ImmunityBio generated nearly $49 million in third-quarter sales, up about 53% from a year earlier but slightly below the previous quarter. Sales for the first nine months of the year totaled almost $144 million. The company was not providing guidance for 2027 or the current quarter, he said.
Expanded Label and Sales Outlook
Adcock attributed the sequential sales decline in part to the limited size of ANKTIVA’s initial approved market. The drug’s U.S. label was expanded in late October to include the papillary-only population within BCG-unresponsive bladder cancer, he said. The initial label covered carcinoma in situ, or CIS, with or without papillary tumors.
The expanded population represents a market between two and four times larger than the initial one, according to Adcock. He said the company had already seen sales in the newly covered population, but it was too early to determine a growth rate.
“We will see initial sales happening in Q4,” Adcock said, adding that he expected the larger effect in 2027 as physicians work through their processes.
Adcock said FDA approval, alongside National Comprehensive Cancer Network listing, was important for reimbursement and for urology practices concerned about payment risk. He said coverage through the Centers for Medicare and Medicaid Services takes effect immediately with both in place, while the company is working with other payers on broader coverage.
BCG-Naive Trial and Supply
ImmunityBio plans to submit a supplemental biologics license application this year for ANKTIVA in high-risk patients who have not previously received BCG, Adcock said. The trial met its primary endpoint of complete response at six months, with a p-value of 0.01, he said.
Adcock did not provide response rates or other detailed results. He said the company is holding those data for presentation at a medical congress and will include available duration data in its submission.
Asked about shortages of BCG, which is used in combination with ANKTIVA, Adcock said more than 1,000 patients had received recombinant BCG through an expanded-access program. ImmunityBio has an exclusive global license for the recombinant product from Serum Institute, he said.
The company also has exclusive rights to the Tokyo-172 BCG strain and is working with the FDA on both products. Adcock said he could not provide an approval timeline, though he thought Tokyo BCG might be approved faster because of the size of a completed comparative trial.
International Business and Pipeline
Adcock said changes related to U.S. most-favored-nation drug pricing policy caused ImmunityBio to reconsider its European launch plans. The company subsequently launched in Germany and Austria with distributors and recorded initial sales, he said.
ImmunityBio reported $334 million in cash for the quarter, Adcock said. Beyond bladder cancer, he pointed to lung cancer trials and an FDA-authorized, randomized Phase 2 sepsis trial. Cleveland Clinic is expected to be among the first sites to open the sepsis study, which will have a 28-day readout, he said.
About ImmunityBio (NASDAQ:IBRX)
ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
